Bibliografía
1. Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol. 2012 May-Jun;46(5):356-66.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4.
3. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug;109 Suppl 1:S2-26; quiz S27.
4. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al; Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007 Dec;56(12):1770-98. Erratum in: Gut. 2008 Dec;57(12):1743.
5. Rey E, Balboa A, Mearin F. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences. Am J Gastroenterol. 2014 Jun;109(6):876-84.
6. Tillisch K, Labus JS, Naliboff BD, Bolus R, Shetzline M, Mayer EA, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol. 2005 Apr;100(4):896-904.
7. Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel
Disorders. Gastroenterology. 2016 Feb 18. pii: S0016-5085(16)00222-5.
8. Saha, L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J. Gastroenterol. 2014, 20, 6759–6773.
9. Rey Díaz-Rubio E, Mascort Roca JJ, Peña Forcada E, Cañones Garzón P, Tenias Burillo JM, Júdez Gutiérrez FJ. Management of the clinical issue of constipation with abdominal complaints in adults. A national survey of Primary Care physicians and gastroenterologists. Rev Esp Enferm Dig. 2016 Jun;108(6):323-31.
10. Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, et al. Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016 Jun;108(6):332-63.
11. Rey E, Mearin F, Alcedo J, Ciriza C, Delgado-Aros S, Freitas T, et al. Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report. Adv Ther. 2017 Mar;34(3):587-598.
12. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther. 2011 Apr;130(1):71-82.
13. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35.
14. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010 Mar;22(3):312-e84.
15. Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology. 2013 Dec;145(6):1334-46.e1-11.
16. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725.
17. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov;107(11):1702-12.
18. Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013 Jan;37(1):49-61.
19. Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, et al. An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6.
20. Tse Y, Armstrong D, Andrews CN, Bitton A, Bressler B, Marshall J, et al.Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. Can J Gastroenterol Hepatol. 2017; 2017:8612189.
21. Lacy BE, Lembo AJ, Macdougall JE, Shiff SJ, Kurtz CB, Currie MG, et al.
Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. Neurogastroenterol Motil. 2014 Mar;26(3):326-33.
22. Andresen V, Diemert S, Miehlke S, Beck E, Prechtl A, Layer P. Effectiveness and tolerability of linaclotide in the treatment of ibs-c in a real-world setting: results from a german non-interventional study. Disponible en https://uegw.congress-online.com/guest/IDe74b14611d0e7e/AbstractView?ABSID=10829 Último acceso 05 de junio 2017.
23. Shearer J, Paine P, Rej A, Agrawal A, Ford AC. Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. Gastroenterology. 2016; 150 (4): S737-S738.
24. Serrano B, Delgado-Aros S, Mearin F, Ciriza de los Ríos C,
Serra J, Mínguez Pérez M, et al. Respuesta de los síntomas intestinales,
No intestinales y extradigestivos a linaclotida en pacientes con síndrome del intestino irritable con estreñimiento: la respuesta a las 4 semanas de tratamiento predice la respuesta mantenida [P 209]. Gastroenterol Hepatol. 2017;40(3):166.
25. Mínguez Cortes JM. Evaluación de tratamiento con linaclotida en un hospital comarcal. P40. Disponible en https://www.sapd.es/revista/article.php?file=vol38_n5_reunion/25 Último acceso 26 de mayo 2017.
26. Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials. 2016 Apr;13(2):161-8.